JSLL Jeena Sikho Q4 FY25 results (Jan–Mar 2025) and concall
Jeena Sikho Lifecare delivered strong financial and operational performance in FY25, driven by robust growth in its service vertical and significant bed capacity expansion. The company is strategically shifting to an asset-light model through college tie-ups for future bed additions and is preparing to launch new OTC products. Management addressed concerns regarding government receivables and non-operational beds, outlining steps to mitigate risks and enhance transparency.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 114 | 116 | 139 |
| EBITDA | 40 | 30 | 46 |
| Net profit | 27 | 13 | 25 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
